PT  - JOURNAL ARTICLE
AU  - Folke Brinkmann
AU  - Anne Schlegtendal
AU  - Stefanie Dillenhoefer
AU  - Cordula Koerner-Rettberg
TI  - Usefulness of measurement of tobramycin levels in the era of once daily iv-treatment
AID  - 10.1183/13993003.congress-2020.691
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 691
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/691.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/691.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: Aminoglykosides have been part of standard treatment for pseudomonas infection in patients with cystic fibrosis for decades. Nephro- and ototoxicity are the most common side effects. Therefore monitoring of tobramycin levels is recommended. The aim of the study was to evaluate the impact of measuring tobramycin levels in once daily iv tobramycin therapy.Methods: All once daily tobramycin treatments between 07/2010 and 07/2019 in CF patients were included and patient data analysed for tobramycin levels, renal function and comorbities.Results: Out of 278 iv tobramycin courses seven elevated tobramycin levels were recorded (2.5%). Six of the measurements (86%) were performed in patients with chronic renal failure.Method: In absence of additional comorbitites and risk factors the monitoring of tobramycin levels in once daily iv treamtent in CF patients is not necessary.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 691.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).